生命科学资讯
生物技术与制药领域的最新动态
A cut above: Veradermics locks in $256M IPO and shares spike
Angitia raises $130M to challenge Amgen with bone-building bispecifics
GE HealthCare posts higher full-year revenues amid turbulent tariff backdrop
Eikon纳斯达克上市融资3.81亿美元,创2024年以来生物科技领域最大IPO纪录。
Eikon's upsized $381M Nasdaq listing marks largest biotech IPO since 2024
Quell暂停肝脏移植Treg试验,专注临床前“冷却非杀伤”候选药物。
Quell halts liver transplant Treg trial to focus on preclinical 'chill not kill' candidate
2026年政府资助法案重启FDA罕见儿科疾病凭证计划
FDA’s rare pediatric disease voucher program revived by 2026 government funding bill
诺华调整早期研发管线:剔除6个项目,新增2个癌症候选药物。
Novartis shakes up early pipeline with 6 culls and 2 new cancer candidates
礼来放弃Prevail收购案中三项管线药物,包括基因疗法,交易价值10亿美元。
Lilly drops 3 pipeline drugs, including gene therapy, from $1B Prevail buyout
葛兰素史克新任CEO寻求20亿至40亿美元“显而易见”的交易机会。
GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight'
美敦力加码收购以色列医疗设备公司CathWorks,交易金额高达5.85亿美元。
Medtronic steps up with up to $585M deal for Israeli devicemaker CathWorks
FDA要求雅培就Libre检查违规问题作出更好回应。
FDA demands better response from Abbott over Libre inspection violations
临床前干细胞生物科技公司PrimeGen选择SPAC方式登陆纳斯达克。
Preclinical stem cell biotech PrimeGen takes SPAC route to Nasdaq
Hims & Hers将通过其数字健康平台销售Grail的Galleri多癌血液检测服务。
Hims & Hers to sell Grail’s Galleri multi-cancer blood test via its digital health platform
NHS“FIT”肠癌检测减少不必要转诊,癌症病例数保持稳定。
NHS 'FIT' bowel cancer test reduced unnecessary referrals as cancer numbers remain stable
诺和诺德CEO“祝辉瑞好运”但继续寻求自有月度GLP-1药物
Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1
安进在狼疮治疗上迈向救赎,胃癌候选药物却遇挫。
Amgen advances toward lupus redemption while gastric cancer candidate struggles
美国卫生与公众服务部启动1亿美元抗病毒药物奖,旨在开发广谱疗法。
HHS launches $100M antiviral prize to develop broad-spectrum therapies
NIH风波成焦点,主任承认疫苗与自闭症无关。
NIH turmoil takes center stage as director acknowledges no vaccine-autism link
辉瑞CEO宣布,在完成六项早期项目削减及44亿美元减值后,管线优化已基本完成。
Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges